文献速递白血病

ASXL1/SRSF2共突变急性髓系白血病的基因组特征与预后意义

Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2021-02-15

该多机构回顾性分析评估了43例ASXL1/SRSF2共突变AML患者的遗传特征与临床结局,并与ASXL1单突变(n=57)或SRSF2单突变(n=70)患者比较。共突变组60%为继发性AML,中位OS为7.0个月,新生AML vs 继发性AML的OS为15.3 vs 6.4个月(P=.04)。共突变患者死亡风险分别较单突变组增加1.4倍和1.6倍(P=.049),OS差异可能归因于继发性AML比例较高。

要点

  • ASXL1/SRSF2共突变AML常与继发性AML相关(60%),中位OS仅7.0个月。
  • 新生AML患者OS显著优于继发性AML(15.3 vs 6.4个月,P=.04)。
  • 共突变组死亡风险较ASXL1或SRSF2单突变组分别增加1.4倍和1.6倍(P=.049)。

核心结论

  • ASXL1/SRSF2共突变AML是常与继发性AML相关的独特亚群,其病因学和白血病发生机制不同于单突变患者。

研究设计与样本

  • 多机构回顾性分析,纳入43例ASXL1/SRSF2共突变AML患者,并与57例ASXL1单突变和70例SRSF2单突变患者比较。

主要发现

  • 共突变组中位OS为7.0个月(95%CI:3.8,15.3)。
  • 新生AML vs 继发性AML的中位OS为15.3 vs 6.4个月(校正分析P=.04)。
  • 共突变患者死亡风险较ASXL1单突变和SRSF2单突变分别增加1.4倍和1.6倍(P=.049)。
  • 三组中位OS分别为7.0、11.5、10.9个月,组间比较P=.10。

关键数值与推荐

  • 变异等位基因分数提示SRSF2突变先于ASXL1突变事件发生。
  • 多变量分析提示OS差异可归因于共突变队列中继发性AML比例较高(60% vs 32%和23%)。

临床怎么用

  • 对ASXL1/SRSF2共突变AML患者应关注继发性AML背景,其预后可能较差。

局限性

  • 回顾性数据收集。
  • 样本量相对较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ASXL1 and SRSF2 mutations in AML are frequently found in patients with preexisting myeloid malignancies and are individually associated with poor outcomes. In this multi-institutional retrospective analysis, we assessed the genetic features and clinical outcomes of 43 patients with ASXL1mut SRSF2mut AML and compared outcomes to patients with either ASXL1 (n = 57) or SRSF2 (n = 70) mutations. Twenty-six (60%) had secondary-AML (s-AML). Variant allele fractions suggested that SRSF2 mutations preceded ASXL1 mutational events. Median overall survival (OS) was 7.0 months (95% CI:3.8,15.3) and was significantly longer in patients with de novo vs s-AML (15.3 vs 6.4 months, respectively; P = .04 on adjusted analysis). Compared to ASXL1mut SRSF2wt and ASXL1wt SRSF2mut , co-mutated patients had a 1.4 and 1.6 times increase in the probability of death, respectively (P = .049), with a trend towards inferior OS (median OS = 7.0 vs 11.5 vs 10.9 months, respectively; P = .10). Multivariable analysis suggests this difference in OS is attributable to the high proportion of s-AML patients in the co-mutated cohort (60% vs 32% and 23%, respectively). Although this study is limited by the retrospective data collection and the relatively small sample size, these data suggest that ASXL1mut SRSF2mut AML is a distinct subgroup of AML frequently associated with s-AML and differs from ASXL1mut SRSF2wt /ASXL1wt SRSF2mut with respect to etiology and leukemogenesis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Richardson DR, Swoboda DM, Moore DT, et al. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia. Am J Hematol. 2021. PMID: 33502020. doi:10.1002/ajh.26110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。